Abstract: Heart failure, as a common, incurable and life-threatening condition, is a fortress we have yet to conquer. The NO-sGC-cGMP pathway plays an important role in endothelial function and myocardial energy metabolism. Vericiguat is the first drug in the field of heart failure that has achieved positive results for this pathway, providing new perspectives and methods for clinical treatment of heart failure. In this paper, the research progress of soluble guanylate cyclase agonist vericiguat in the field of heart failure was reviewed, including the mechanism of action of vericiguat in the treatment of heart failure, preclinical studies, clinical studies and its progress in China, with the aim for rational clinical administration of vericiguat.